ArticleOcular oncology and pathology2026
Impact of Chemotherapy and Radiotherapy on Iris Metastases: A Case Report.
Article in Ocular oncology and pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Iris metastases are a rare initial presentation of a systemic malignancy, managed with chemotherapy and radiotherapy in most cases. These cases provide visual documentation of iris metastasis resolution following chemotherapy and radiotherapy and illustrate potential adverse effects associated with treatment response, including intraocular pressure variations and development of iris synechiae. Case Presentation: Two cases presented to metropolitan hospitals with ocular pain, which on ophthalmic review, revealed the presence of vascularised iris lesions. One case had a history of lung adenocarcinoma, on maintenance chemotherapy in addition to palliative radiotherapy to other metastatic deposits (case 1), whilst the other had no known history of malignancy (case 2). Case 2 required extensive investigations to obtain a histopathological diagnosis and stage the malignancy, after which he received chemotherapy followed by radiotherapy. In contrast, case 1 proceeded with immediate management with radiotherapy, followed by chemotherapy. Following the commencement of either treatment modality, tumour response was noted, with corresponding elevations in intraocular pressure, which was managed with topical glaucoma eye drops in addition to systemic acetazolamide. Both cases experienced complete remission of their iris metastases, though case 1 had extensive iris synechiae and case 2 passed away due to a rapid decline in their systemic malignancy. Conclusion: Our case offers a unique visual insight into the impact of both systemic chemotherapy and localised radiotherapy on uncommon iris metastases, with sequential images taken at each stage of treatment. We underscore the importance of continual monitoring of the intraocular pressure during treatment, as tumour response was associated with elevated intraocular pressures in both of these cases. We hypothesise that this may be due to a combination of tumour liquefaction and hyphaema blocking trabecular meshwork outflow. Finally, despite treatment of the iris metastasis, patients may be left with residual iris synechiae, requiring additional surgical intervention to manage the intraocular pressure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.